Menu

American Retired Seniors

Just another WordPress site

Eric Lefkofsky Introduces Human Genome Sequencing Technology to Treat Cancer

Cancer is one of the leading killer diseases. In the United States, 40 percent of the adults are diagnosed with cancer. The National Cancer Institute estimated that 14.5 million adults were diagnosed with cancer and the figure is expected to grow 19 million by 2024. However, the situation may be less harsh in the future if the data enabled precision medicine technology spearheaded by Eric Lefkofsky, the co-founder of Tempus and Groupon.

Since the development of electronic health records (EHR) was faced by a lot of resistant, the healthcare industry is technologically railing. When Eric Lefkofsky wife was diagnosed with cancer, he was shocked to identify the huge gaps in the health sector, especially data collection technology. Although a lot of data had been collected from patients, it remained raw data and wasn’t effective.

After realizing the huge gap, Eric came with the idea of Tempus. With a goal to transform the cancer treatment sector, Tempus developed a platform that could excellently analyze clinical and molecular data obtained from patients. Although the firm had enough muscles to develop analytical software, affordable and accessible medical and clinical data presented a major hurdle. Collecting and storing patient data was the other shortcoming.

After overcoming all the challenges, Tempus developed software that promotes human genome sequencing. Eric believes that human genes hold the secret that once revealed, cancer treatment could become easier. As more data is being collected, compared, paired and analyzed, the secrets will be unlocked. With time doctors will be able to make real time decisions and identify, which medicine responds positively.

Eric Lefkofsky

Eric Lefkofsky is a decorated entrepreneur and a philanthropist. He is the co-founder of Groupon and Tempus. The shrewd entrepreneur is also the founder of Uptake Technologies, Lightbank, InnerWorkings, Echo Global Logistics and Mediaocean. Lefkofsky graduated with a bachelor’s degree from the University of Michigan before joining The University of Michigan Law School where he graduated with JD. For more info about us: https://www.tempus.com/about-us/ click here.

In 2006, Eric Lefkofsky and his wife founded Lefkofsky Family Foundation, an organization that focuses on charitable causes. Through the foundation, Eric has been able to improve the quality of life, fight for human rights, better health care as well as supporting education and art initiatives.

Oncotarget Continues to Grow to Help Patients

As Oncotarget has grown, Mikhail Blagosklonny has taken it from something that was targeted specifically at those who were working in the oncology field to something that will be able to help people with the issues that they are having in their own medical specialty. He has improved all of the options that people have in their own medical field and has also given them the chances that they need to make things better for themselves and for the others that they are working with in their own fields.

While the main goal that Mikhail Blagosklonny had for Oncotarget was to help doctors figure out what they needed to do to make things better for all of their patients, an indirect result has been the help that it has brought to all of the patients that the doctors are helping. Mikhail Blagosklonny knew that this would happen and he also wanted to make sure that it was something that people would be able to enjoy because of all of the options that came along with it. He wanted people to be aware of the help that they could receive from Oncotarget and wanted to make sure that they were getting everything that they needed while they were in different situations. He had hoped that this would bring in everything that each person needed while they were battling cancer and he hoped that the doctors would be able to use the information that was found in the publication. Check the journal at SCImago Journal & Country Rank.

For Oncotarget, there are many different options that people will be able to enjoy. One of the key parts of the publication is to connect doctors who work in different fields and who may not have the chance to connect otherwise. In no other peer review publication can an endocrinologist and an oncologist make the right type of connection that they need to come up with a treatment plan for someone with cancer. It has been a huge help in the area that they are in and has also made it easier for people to get what they need out of the options that they have to treat their patients.

Visit: https://www.facebook.com/Oncotarget/

Eric Lefkofsky Is Changing Lives With the Help of Tempus

Does the name Eric Lefkofsky sound familiar? Have you heard this name previously? If you haven’t, the name Groupon should ring a bell. Eric is the creator of Groupon and as of right now, he remains a shareholder of the business but has decided to use his energy to focus more on his new business venture, Tempus.Tempus is a fairly new concept that allows for patients to have their DNA analyzed by professionals who can aim a better treatment plan towards their individual health needs. The Tempus business is partnered with a large collection of prominent hospitals that work with those in labs to help better understand the DNA of the cancer patients. The database will collect specific genomic DNA to compare to others and then begin a treatment plan specific to each individual case.

Technology is always changing and for this reason, someone needed to come up with a better understanding of the data needed for patients in order to help patients be treated better for their cancer. With Tempus, the technology is there to help those live longer lives than before. Now the physicians are able to collect all the information they need to make a better and more informed plan for their patients.There are a number of nonprofits as well as startups that work to help to find a cure or treatment of a disease.

The business industry is able to screen for more things as the cost has decreased to perform certain tests than ever before. It is also easier and cheaper to store the data needed to perform tests and get results.Because Eric worked hard to partner with prominent hospitals, the data that is collected is stored and analyzed. There is a 20,000 square foot lab that is used primarily for collecting and analyzing all data. This lab helps to build a DNA database as well as a patient profile which is used to help cancer patients.

 

Eric Lefkofsky, the Co-Founder of Tempus

As written in the article, “This Is What’s Missing in the Data-Centric Approach to Cancer”, by Barb Darrow, doctors need a lot of data, to make good decisions, for their patient’s treatment of cancer. Eric Lefkofsky co-founded the company Tempus, when his wife was diagnosed with cancer, and he realized the doctors weren’t using all of the data they had available to them. There were privacy issues blocking the collection of data from hospitals, doctors, and researchers, and he felt it was necessary to share the results of their treatments on the many people who came through their doors. With all the different medical issues and medications they each took, the results of their treatments were all different.

The new data will alert the doctors to multiple patient results, and they will be better equipped to determine which treatment is best for their patient. Tempus is designed to collect their patient’s records, take the personal information from the record, and give the treatment results back to the doctors, researchers, and hospitals, so that they can properly analyze what has been working and not working so well on their patients. Lefkofsky would like to see cancer patients treated on a more individual basis for their needs. He would also like to see companies, like CRISPR, who are looking into personalized vaccines to use the data for their own research.

Mr Lefkofsky earned his law degree from the University of Michigan Law. In 1994 he and his business partner, Bradley Keywell, took out a loan to buy Brandon Apparel, but it went under. In 1999, they started an internet business called, Starbelly, which they were able to sell for $240 million. Since then, Lefkofsky has co-founded Tempus, Lightbank, Groupon, Uptake Technologies, Mediaocean, InnerWorkings, and Global Logistics. He also started a foundation with his wife, Liz, called, the Lefkofsky Family Foundation. The foundation is private and focuses on improving the communities in the Chicago area, as well as, around the world. Eric Lefkofsky – Co-founder and CEO @ Tempus | Crunchbase

Clay Siegall’s Brilliant Role In Seeking Solutions To Cancer

Clay Siegall is the co-founder and chief executive officer of Seattle Genetics; a pharmaceutical company focused on developing biotechnology solutions for cancer. Under Siegall’s tenure, the group has developed innovative products including the much known antibody-drug conjugates aimed at helping patients. Clay Siegall was also influential in seeking the certification of the firm’s first antibody-drug conjugate, ADCETRIS by the Food and Drug Administration in 2011.

 

In a recent interview, Clay opened up on his role at Seattle Genetics and also shared his success story. Clay Siegall’s father was diagnosed with cancer when he was just nineteen years old. Unfortunately for him, he watched helplessly as his father’s condition deteriorated and he succumbed five years later, leaving Clay devastated. He was only twenty-four then, and when he earned a doctorate in genetics, he set on a path to help cancer patients. He did this by joining pharmaceutical research institutes the like of Bristol-Myers Squibb. It was here that he gained experience in running a company and had a chance to improve his leadership skills further. The work also brought him to Seattle and with the skills he had acquired, he founded Seattle Genetics with a commitment to treating cancer.

 

In his entrepreneur journey, Clay Siegall has learned the habit of seeking knowledge and interacting with deeply knowledgeable individuals as the key secret to success. Siegall is also apprehensive of the fact that progress in anything needs strong partnerships. This has been Seattle Genetics group’s primary business strategy as they have collaborated with other companies. This has led to the development of new ideas and approaches that have extended the firm’s reach, therefore, helping more patients.

 

About Clay Siegall

 

Clay Siegall is the co-founder of Seattle Genetics and also serves as the group’s President, CEO, and Chairman of the Board. Clay is a professional geneticist and holds an array of academic credentials including a doctorate in Genetics from George Washington University.

 

Apart from his role at Seattle Genetics, Clay Siegall also sits on boards of different corporations in diverse industries. Siegall is also the author of numerous publications and holds numerous patents.

The Incredible Technologies And Work Of The Cancer Treatment Centers Of America

The Cancer Treatment Centers of America have entered into a collaboration with Allscripts and NantHealth. They have implemented a solution that will improve the information available regarding cancer treatments. This involves the integration of the Clinical Pathways program which contains the input of oncologists all over the nation.

According to Wikipedia, the system will show all of the appropriate treatments that are available. Any guesswork will be almost completely eliminated. Everything is customized with the CTCA standards of care so patients can choose from safe and efficient options. The Clinical Pathways system was designed to focus on the patients and has the latest treatments, complimentary therapies and a curated protocol list pertaining to diseases specific to the patients.

The options are available by tapping the screen and combines supportive therapies with clinical based evidence. The system is designed to meet the individual needs of each patient and improve the quality of their lives while they are receiving treatments for cancer. The guidelines also include adverse drug reactions and response rates.

Patients and the staff now have the ability to discuss the different treatment regimens available and what the best treatment would be for the patients particular situation. The data supporting the options is also easily available. Physicians now have access to a medical library containing more than 2,700 pieces of evidence based treatments and appropriate therapies. All cancers, modalities and subtypes are covered in the system.

The blog, https://www.myctca.com/ for Cancer Treatment Centers Of America are based out of Boca Raton, Florida but operate on a national basis. They are a network of five profit based hospitals who serve patients with cancer all over the United States. They use conventional approaches including chemotherapy, immunotherapy, surgery and radiation. They also offer therapies to help patients with pain, fatigue, malnutrition, anxiety, depression and lymphedema.

Richard Stephenson founded CTCA in honor of his mother after she passed away from cancer. He was dissatisfied with available treatment options so he opened the first CTCA location in 1988. The hospital was in Zion, Illinois and the other four locations opened between 2005 and 2012.

For more information on Cancer Treatment Centers of America follow them on Facebook.

 

Mikhail Blagosklonny/ Innovative Research Against Cancer

Mikhail Blagosklonny is a scientist that is involved in cancer research and aging. Mikhail Blagosklonny is currently a professor of oncology at the esteemed Roswell Park Cancer Institute, a position he was appointed to in 2009. Blagosklonny obtained his M.D in internal medicine from Pavlov State Medical University of St. Peterburg. He also received his PhD in experimental medicine and cardiology from the same university. During his career Blagosklonny has researched and investigated many different avenues regarding cancer and its devastating effects.

He has developed theories and approaches that can one day revolutionize cancer treatment. Mikhail Blagosklonny has a broad range of research interests, from molecular and cellular biology to clinical investigations. Some of his research is specifically inclusive of cell cycle, apoptosis, mitosis, signal transduction, oncogenes and tumor suppressors. Blagosklonny, because of his in-depth research has become a strong advocate for the use of Rapamycin a possible life extending drug in the fight against cancer and has a strong hypothesis regarding the role of TOR signaling in cancer and aging.

Rapamycin in regards to cancer seems to suppress tumors and is known to increase lifespan in mice. Targeted cancer therapies that do not target healthy cells are of special interest in his research. Before Mikhail Blagosklonny’s position at Roswell Park Cancer Institute, Blagosklonny previously held positions as Associate Professor of medicine at New York Medical College, Valhalla, NY and Senior Scientist at Ordway Research Institute, Albany, NY. Mikhail Blagosklonny has published 300 research articles including reviews and book chapters.

He is the editor of several publications including Cell cycle, and Aging both of which he was editor and chief. He was also a member of the editorial board for Cell Death and Differentiation and was associate editor of Cancer Biology and Therapy. Mikhail Blagosklonny is also the author of anti-cancer approaches also known as chemotherapeutic engineering and cell cyclotherapy. He continues to aid in the fight against cancer with his dedication to performing innovative and groundbreaking research. View his LinkedIn profile.